2019
Ruxolitinib, a selective JAK1/2 inhibitor, for the treatment of serious diseases caused by Staphylococcus aureus superantigens
Carnes H, Mehrkens B, Stegman M, Rajagopalan G. Ruxolitinib, a selective JAK1/2 inhibitor, for the treatment of serious diseases caused by Staphylococcus aureus superantigens. The Journal Of Immunology 2019, 202: 190.34-190.34. DOI: 10.4049/jimmunol.202.supp.190.34.Peer-Reviewed Original ResearchSystemic inflammatory response syndromeMulti-organ failureT cellsHLA-DR3 transgenic miceHLA class II moleculesVehicle-treated miceVivo studiesInflammatory response syndromeT cell subsetsToxic shock syndromeJAK 1/2 inhibitorSelective JAK1/2 inhibitorClass II moleculesStaphylococcus aureusDose-dependent mannerSerious diseaseJanus kinaseIL-17Response syndromeOrgan failureJAK1/2 inhibitorActivation markersCell subsetsShock syndromeIL-2
2012
Detrimental effects of T regulatory cell-promoting IL-2-anti-IL-2 complexes in staphylococcal toxic shock syndrome. (164.13)
Rajagopalan G, Tilahun A. Detrimental effects of T regulatory cell-promoting IL-2-anti-IL-2 complexes in staphylococcal toxic shock syndrome. (164.13). The Journal Of Immunology 2012, 188: 164.13-164.13. DOI: 10.4049/jimmunol.188.supp.164.13.Peer-Reviewed Original ResearchToxic shock syndromeHLA-DR3 transgenic miceTreg numbersShock syndromeNon-menstrual toxic shock syndromeTransgenic miceCytokine/chemokine stormStaphylococcal toxic shock syndromeNumber of TregsMultiple organ failureStaphylococcal enterotoxin BChemokine stormMIP-1βOrgan failureMIP-1αUntreated groupSuperantigen exotoxinsDay 5Immune systemDay 0IL2CMiceEnterotoxin BStreptococcus pyogenesAdministration